Nateglinide pharmacokinetics

Zhou H, Walter YH, Smith H, Devineni D, McLeod JF. Nateglinide, a new mealtime glucose regulator. Lack of pharmacokinetic interaction with digoxin in healthy volunteers. Clin Drug Invest 2000 19 465-71. 

Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005 60 208 117. 

In a randomised, double-blind study, 11 healthy subjects were given nateglinide 120 mg three times daily for 5 days, with a single 10-mg dose of acenocoumarol on day 3. Nateglinide had no effect on the tolerability, pharmacokinetics or anticoagulant activity of acenocoumarol. ... 

In another study,12 healthy subjects were given nateglinide 120 mg three times daily for 4 days with a single 30-mg dose of warfarin on day 2. No pharmacokinetic or pharmacodynamic interaction was noted. No dosage adjustments would therefore be expected to be necessary if nateglinide is taken with either acenocoumarol or warfarin. 

Itraconazole also appears not to affect diabetic control in most patients, but there are reports of hypoglycaemia or hyperglycaemia associated with its use. Itraconazole causes modest increases in repaglinide and nateglinide levels, but has no effect on pioglita-zone pharmacokinetics. Ketoconazole increases the blood glu-... 

The modest changes in repaglinide pharmacokinetics with ketoconazole and itraconazole may be because repaglinide is metabolised by both CYP2C8 and CYP3A4, and one pathway may have the capacity to compensate if the other is inhibited. Similarly, itraconazole modestly affects nateglinide metabolism via CYP3A4. ... 

In a randomised crossover study, 18 healthy subjects were given modi-fied-release diclofenac 75 mg on the same day as two 120-mg doses of nateglinide, given 4 hours apart. The pharmacokinetics of both drugs were unaltered by concurrent use. ... 

Anderson DM Shelley S, CrickN,BuraglioM.A3-way crossover stucfy to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. IntJ Clin... 

Sabia H, Sunkara G, Ligueros-Saylan M, Wang Y, Smith H, McLeod J, Prasad P. Effect of a selective CYP2C9 inhibitor on tiie pharmacokinetics of nateglinide in healthy subjects. EurJ Clin Pharmacol epOA) 60,407-12. 

Only the D-enantiomer of nateglinide is approved to be used in clinical treatment because it is much more potent than the L-enantiomer. Some works were developed for determination of the L-enantiomer in bulk dmg substance of nateglinide. The assay of Cao et al. " allows the accurate and precise measurement of o-nateglinide and its enantiomer during pharmacokinetic studies in humans. The interday precision values for both enantiomers in plasma and urine are about 7% and 10%, respectively. 

Anderson, D.M. Shelley, S. Crick, N. Buraglio, M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers, J.CUn.Phar-macoL, 2002, 42, 1358-1365. [LOQ 50 ng/mL SPE column-switching]... 

Choudhury, S. Hirschberg, Y. Filipek, R. Lasseter, K. McLeod, J.F. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis, J.Clin.Pharmacol., 2000, 40, 634-640. [SPE LOQ 25.8 ng/mL]... 

---